The antimicrobial peptide protegrin-1 inhibited a key dengue virus enzyme at IC₅₀ of 11.7 μM and significantly reduced dengue-2 viral replication in monkey kidney cells.
IC₅₀ = 11.7 μMProtegrin-1's concentration needed to inhibit 50% of dengue NS2B-NS3 protease activity, demonstrating a starting point for peptide-based dengue drug development
What the researchers found
Protegrin-1 (PG-1) inhibited dengue NS2B-NS3 serine protease with an IC₅₀ of 11.7 μM. When tested against dengue serotype-2 (DENV-2) replication in MK2 cells, graded concentrations of PG-1 at non-toxic doses significantly reduced viral replication (p < 0.001) at 24, 48, and 72 hours post-infection.
The percentage of inhibition was significantly higher at 24 hours compared to 48 and 72 hours (p < 0.01), suggesting PG-1 is most effective in the early stages of viral replication. The peptide was synthesized with correct disulphide bond formation confirmed by LC-MS and RP-HPLC.
Why it matters
Dengue infects hundreds of millions of people annually and has no approved antiviral treatment. The NS2B-NS3 protease is essential for dengue virus replication and is a validated drug target. Discovering that an existing antimicrobial peptide can inhibit this enzyme opens a new avenue for peptide-based antiviral drug development against dengue.
How the study worked
PG-1 (sequence: RGGRLCYCRRRFCVCVGR) was synthesized by solid-phase peptide synthesis with disulphide bond formation and purity confirmed by LC-MS and RP-HPLC. Dengue NS2B-NS3 protease was produced as a recombinant protein in E. coli. Protease inhibition was measured by fluorescence emission of a catalyzed substrate. Antiviral activity was assessed by real-time PCR quantification of DENV-2 replication in Rhesus monkey kidney (MK2) cells at 24, 48, and 72 hours post-infection.
What this study cannot tell us
This is an in vitro study using cell culture, not an animal or human study. The IC₅₀ of 11.7 μM is relatively high for a drug candidate and would likely need optimization. PG-1's effectiveness decreased over time (strongest at 24 hours), suggesting it may not provide sustained antiviral activity. Peptide stability in vivo and delivery challenges were not addressed. Only dengue serotype-2 was tested.
How to read the evidence
This is an in vitro study using recombinant enzyme assays and cell culture viral replication models. While it provides proof-of-concept for protegrin-1 as a dengue protease inhibitor, it is at an early stage of drug development with no in vivo or clinical data.
When this study was published
Published in 2012, this is an older study that contributed to the early understanding of antimicrobial peptides as potential antiviral agents. Since then, the field of peptide-based antivirals has continued to develop.
The bigger picture
Antimicrobial peptides were originally studied for their antibacterial properties, but their antiviral potential is increasingly recognized. This study expands protegrin-1's known activity spectrum to include dengue virus protease inhibition, adding to the growing evidence that naturally occurring peptides could serve as scaffolds for developing antiviral drugs against tropical diseases with unmet medical needs.
Questions still open
- Can protegrin-1 be modified to achieve lower IC₅₀ values while maintaining its protease inhibitory activity?
- Would PG-1 or its derivatives be effective against all four dengue serotypes?
- Could protegrin-1 be delivered effectively as an antiviral treatment in vivo, given the challenges of peptide stability and bioavailability?
Common questions
What is protegrin-1 and where does it come from?
Why is the dengue protease an important drug target?
Read the original research
Protegrin-1 inhibits dengue NS2B-NS3 serine protease and viral replication in MK2 cells.
Journal of biomedicine & biotechnology, 2012, 251482
Citation
Rothan, Hussin A; Abdulrahman, Ammar Y; Sasikumer, Pottayil G; Othman, Shatrah; Rahman, Noorsaadah Abd; Yusof, Rohana. (2012). Protegrin-1 inhibits dengue NS2B-NS3 serine protease and viral replication in MK2 cells.. Journal of biomedicine & biotechnology, 2012, 251482. https://doi.org/10.1155/2012/251482